Compositions and methods for treatment of ovarian cancer
View Patent ↗The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.
1. A method of inhibiting proliferation of human ovarian cancer cells, the method comprising introducing into the cells a compound which inhibits expression or activity of any one of SEQ ID NOs: 9 and 29, wherein said compound inhibits proliferation of ovarian cancer cells.
2. The method of claim 1 , wherein said compound comprises a modified oligonucleotide consisting of 15 to 30 linked nucleosides, wherein the modified oligonucleotide has a nucleobase sequence that is complementary to any one of SEQ ID NOs: 9 and 29.
3. The method of claim 2 , wherein said modified oligonucleotide has a nucleobase sequence comprising SEQ ID NO: 49.
4. The method of claim 1 , wherein the ovarian cancer cell is selected from the group consisting of serous and endometrioid ovarian cancer cells.
5. The method of claim 2 , wherein the nucleobase sequence of the modified oligonucleotide has none, one or two mismatches to a nucleobase sequence comprising SEQ ID NO: 49.
6. The method of claim 2 , wherein at least one internucleoside linkage is a modified internucleoside linkage.
7. The method of claim 2 , wherein said modified internucleoside linkage is a phosphorothioate internucleoside linkage.
8. The method of claim 2 , wherein at least one nucleoside comprises a modified sugar.
9. A method for treating ovarian cancer in a human subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising a modified oligonucleotide consisting of 15 to 30 linked nucleosides, wherein the modified oligonucleotide has a nucleobase sequence that is complementary to any one of SEQ ID NOs: 9 and 29, wherein said composition treats ovarian cancer.
10. The method of claim 9 , wherein the modified oligonucleotide has a nucleobase sequence comprising at least 15 contiguous nucleobases of a nucleobase sequence comprising SEQ ID NO: 49.
11. The method of claim 9 , wherein the ovarian cancer is selected from the group consisting of serous and endometrioid ovarian cancer.
12. The method of claim 9 , wherein the nucleobase sequence of the modified oligonucleotide has none, one or two mismatches to SEQ ID NO: 49.
13. The method of claim 9 , wherein at least one internucleoside linkage is a modified internucleoside linkage.
14. The method of claim 9 , wherein said modified internucleoside linkage is a phosphorothioate internucleoside linkage.
15. The method of claim 9 , wherein at least one nucleoside comprises a modified sugar.
16. The method of claim 9 , wherein said composition is administered by any one of intravenous administration, subcutaneous administration, intra-tumor administration, or chemoembolization.
17. The method of claim 9 , further comprising administering at least one additional therapy, wherein said additional therapy is administered at the same time as, more frequently, or less frequently than the composition comprising the modified oligonucleotide.
18. The method of claim 17 , wherein the at least one additional therapy is a chemotherapeutic agent.
19. The method of claim 18 , wherein the chemotherapeutic agent may be selected from cisplatin, carboplatin, camptothecins, doxorubicin, cyclophosphamide, paclitaxel, etoposide, vinblastine, Actinomycin D and cloposide.
20. The method of claim 9 , wherein said composition comprises a modified oligonucleotide at a dose between and including 50 and 800 mg; and wherein said composition is administered once a day, once per week, once per two weeks, once per three weeks, or once per four weeks.
21. The method of claim 9 , wherein the treatment results are selected from the group consisting of reduction of tumor size, reduction in tumor number, preventing the increase in tumor size, preventing the increase in tumor number, slowing metastatic progression and stopping metastatic progression.
22. The method of claim 8 , wherein the modified sugar is a 2′-O-methoxyethyl sugar.
23. The method of claim 15 , wherein the modified sugar is a 2′-O-methoxyethyl sugar.